<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35470643</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2191-0251</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pediatric endocrinology &amp; metabolism : JPEM</Title>
          <ISOAbbreviation>J Pediatr Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rituximab therapy in ROHHAD(NET) syndrome.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1515/jpem-2022-0085</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation, and neural-crest tumour (ROHHAD(NET)) is a rare syndrome presenting in early childhood associated with high morbidity and mortality. There is no specific diagnostic biomarker and diagnosis is based on clinical features. An autoimmune origin has been postulated.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">Management is largely supportive. We report a case of a five-year old female who presented in respiratory arrest after 6-months of rapid weight gain. She had central hypoventilation, central diabetes insipidus, growth hormone deficiency and hyperprolactinaemia. She displayed elevated interleukin-6 levels on cytokine serology which normalised after rituximab treatment. After rituximab treatment, her weight reduced significantly from greatly above the 99.6th to the 50th centile in 12 months.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This response possibly reflects an underlying, immune-inflammatory pathology driving excess adiposity in this condition. Potentially, other aspects of ROHHAD(NET) may be mediated through autoimmune dysregulation in which case rituximab may provide benefits for prognosis and survival.</AbstractText>
          <CopyrightInformation>© 2022 Walter de Gruyter GmbH, Berlin/Boston.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hawton</LastName>
            <ForeName>Katherine Ac</ForeName>
            <Initials>KA</Initials>
            <Identifier Source="ORCID">0000-0002-9448-0935</Identifier>
            <AffiliationInfo>
              <Affiliation>Bristol Royal Hospital for Children, Bristol, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Bristol, Bristol, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Doffinger</LastName>
            <ForeName>Rainer</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramanan</LastName>
            <ForeName>Athimalaipet V</ForeName>
            <Initials>AV</Initials>
            <AffiliationInfo>
              <Affiliation>Bristol Royal Hospital for Children, Bristol, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Bristol, Bristol, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Langton Hewer</LastName>
            <ForeName>Simon C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Bristol Royal Hospital for Children, Bristol, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Bristol, Bristol, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evans</LastName>
            <ForeName>Hazel J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Paediatrics, Southampton Children's Hospital, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giri</LastName>
            <ForeName>Dinesh</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Bristol Royal Hospital for Children, Bristol, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Bristol, Bristol, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamilton Shield</LastName>
            <ForeName>Julian P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>NIHR Biomedical Research Centre (Nutrition Theme), University of Bristol, Bristol, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Pediatr Endocrinol Metab</MedlineTA>
        <NlmUniqueID>9508900</NlmUniqueID>
        <ISSNLinking>0334-018X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ROHHAD</Keyword>
        <Keyword MajorTopicYN="N">hypoventilation</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35470643</ArticleId>
        <ArticleId IdType="doi">10.1515/jpem-2022-0085</ArticleId>
        <ArticleId IdType="pii">jpem-2022-0085</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Reppucci, D, Hamilton, J, Yeh, E, Katz, S, Al-Saleh, S, Narang, I. ROHHAD syndrome and evolution of sleep disordered breathing. Orphanet J Dare Dis 2016;11:106. https://doi.org/10.1186/s13023-016-0484-1.</Citation>
        </Reference>
        <Reference>
          <Citation>Harvengt, J, Gernay, C, Mastouri, M, Farhat, N, Lebrethon, M, Seghaye, M, et al.. ROHHAD(NET) syndrome: systematic review of the clinical timeline and recommendations for diagnosis and prognosis. J Clin Endocr Metab 2020;105:2119. https://doi.org/10.1210/clinem/dgaa247.</Citation>
        </Reference>
        <Reference>
          <Citation>Bougnères, P, Pantalone, L, Linglart, A, Rothenbühler, A, Le Stunff, C. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocr Metab 2008;93:3971–80. https://doi.org/10.1210/jc.2008-0238.</Citation>
        </Reference>
        <Reference>
          <Citation>Giacomozzi, C, Guaraldi, F, Cambiaso, P, Niceta, M, Verrillo, E, Tartaglia, M, et al.. Anti-hypothalamus and anti-pituitary auto-antibodies in ROHHAD syndrome: additional evidence supporting an autoimmune etiopathogenesis. Horm Res Paediat 2019;92:124–32. https://doi.org/10.1159/000499163.</Citation>
        </Reference>
        <Reference>
          <Citation>Ibáñez-Micó, S, Marcos Oltra, A, de Murcia Lemauviel, S, Ruiz Pruneda, R, Martínez Ferrández, C, Domingo Jiménez, R. Rapid-onset obesity with hypothalamic dysregulation, hypoventilation, and autonomic dysregulation (ROHHAD syndrome): a case report and literature review. Neurologia 2017;32:616–22. https://doi.org/10.1016/j.nrl.2016.04.008.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee, JM, Shin, J, Kim, S, Gee, HY, Lee, JS, Cha, DH, et al.. Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neuroendocrine tumors (ROHHADNET) syndrome: a systematic review. BioMed Res Int 2018;2018:1250721. https://doi.org/10.1155/2018/1250721.</Citation>
        </Reference>
        <Reference>
          <Citation>Filippidou, M, Petropoulou, T, Botsa, E, Vasilakis, I, Smyrnaki, P, Orfanou, I, et al.. ROHHAD syndrome - a still unrecognized cause of childhood obesity: report of three cases. J Pediatr Endocrinol Metabol 2020;33:1341–48. https://doi.org/10.1515/jpem-2020-0111.</Citation>
        </Reference>
        <Reference>
          <Citation>Ido Paz-Priel, M, David, W, Cooke, MD, Chen, AR. Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome. J Pediatr 2010;158:337–9. https://doi.org/10.1016/j.jpeds.2010.07.006.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith, M. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359–68. https://doi.org/10.1038/sj.onc.1206939.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
